Concepedia

Publication | Open Access

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

DOIFull Paper Access

2.4K

Citations

13

References

2022

Year

Scott D. Solomon, John J.V. McMurray, Brian Claggett, Rudolf A. de Boer, David L. DeMets, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod, Carolyn S.P. Lam, Felipe A. Martínez,
New England Journal of Medicine

Abstract

Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).

References

YearCitations

Page 1